Researchers Examine Relationship Between CYP2D6 Genotype And Tamoxifen Treatment In Patients With Hormone Receptor-Positive Metastatic Breast Cancer

February 07, 2020

Healio (2/6) reports researchers found in a phase 2 trial that “increasing tamoxifen dosage did not lead to a higher rate of 6-month PFS among patients with hormone receptor-positive metastatic breast cancer who have CYP2D6-variant alleles.” In addition,...